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ABSTRACT
Objectives: To determine the carrier rate of the GJB2
mutation c.35delG and c.101T>C in a UK population
study; to determine whether carriers of the mutation
had worse hearing or otoacoustic emissions compared
to non-carriers.
Design: Prospective cohort study.
Setting: University of Bristol, UK.
Participants: Children in the Avon Longitudinal Study
of Parents and Children. 9202 were successfully
genotyped for the c.35delG mutation and c.101>T and
classified as either carriers or non-carriers.
Outcome measures: Hearing thresholds at age 7, 9
and 11 years and otoacoustic emissions at age 9 and 11.
Results: The carrier frequency of the c.35delG mutation
was 1.36% (95% CI 1.13 to 1.62) and c.101T>C was
2.69% (95% CI 2.37 to 3.05). Carriers of c.35delG and
c.101T>C had worse hearing than non-carriers at the
extra-high frequency of 16 kHz. The mean difference in
hearing at age 7 for the c.35delG mutation was 8.53 dB
(95% CI 2.99, 14.07) and 12.57 dB at age 9 (95% CI
8.10, 17.04). The mean difference for c.101T>C at age 7
was 3.25 dB (95% CI −0.25 to 6.75) and 7.61 dB (95%
CI 4.26 to 10.96) at age 9. Otoacoustic emissions were
smaller in the c.35delG mutation carrier group: at 4 kHz
the mean difference was −4.95 dB (95% CI −6.70 to
−3.21) at age 9 and −3.94 dB (95% CI −5.78 to −2.10)
at age 11. There was weak evidence for differences in
otoacoustic emissions amplitude for c.101T>C carriers.
Conclusion: Carriers of the c.35delG mutation and
c.101T>C have worse extra-high-frequency hearing than
non-carriers. This may be a predictor for changes in
lower-frequency hearing in adulthood. The milder effects
observed in carriers of c.101T>C are in keeping with its
classification as a mutation causing mild/moderate
hearing loss in homozygosity or compound
heterozygosity.
INTRODUCTION
The human gap junction β-2 gene (GJB2)
that encodes the protein connexin 26 was
the ﬁrst autosomal gene to be identiﬁed for
non-syndromic deafness.1 Connexin 26 is
involved in recycling of potassium ions in the
endolymph of the cochlea2 and mutations in
this gene are by far the commonest cause of
autosomal-recessive non-syndromic sensori-
neural hearing loss (NSSNHL) worldwide.
The mutation c.35delG is the most common
mutation causing severe–profound deafness in
Caucasian populations and accounts for
approximately 70% of autosomal recessive
NSSNHL.3 4 The c.35delG carrier rate was eval-
uated by Mahdieh and Rabbani5 who pooled
data from 41 studies, including a review by
Gasparini et al6 in which they estimated the
carrier rate to be highest in Europe with a
mean rate of 1.89%. However within Europe,
there was variation across countries with a
higher rate of 2.48% in Southern Europe com-
pared with 1.53% in Northern Europe.5 This
variation highlights the importance of knowing
the carrier rate for individual countries. There
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are, however, relatively few data from the UK with
Gasparini et al6 ﬁnding 0/119 carriers in the UK arm of
their European study. The high carrier rate of GJB2 muta-
tions is of interest and some have suggested possible het-
erozygote advantage.7 8 Such an advantage would have to
outweigh any negative biological effects on hearing.
There has also been interest in c.101T>C (p.M34T) the
effect of which on hearing is the subject of contention.
c.101T>C (p.M34T) has a higher carrier rate than
c.35delG in Caucasian populations. A US study found 3/
128 carriers,9 giving a rate of 2.3% and Houseman et al10
found a carrier rate of 4.8% in the UK based on a small
sample of 630.
c.101T>C (p.M34T) was ﬁrst described as a dominant
mutation1 and subsequently as a recessive mutation.10–12
In vitro studies have shown that GJB2: p.M34T is cor-
rectly synthesised, locates to the cell membrane nor-
mally, but shows impaired intercellular coupling as
judged by transfer of dyes between neighbouring cells
through the gap junctions. There are also observations
that there is disturbed oligomerisation of GJB2:p.M34T
connexins.13–15 One would therefore expect an effect on
the cochlea and on hearing. Some studies have demon-
strated dominant negative effects of the mutant
(p.M34T) on wild-type connexins15 16 and yet it is clear
from human genetic studies that this is not a dominantly
acting mutation. Indeed many examples exist where
homozygosity for p.M34T/p.M34T or compound hetero-
zygosity p.M34T/c.35delG is associated with normal
hearing17–19 or a signiﬁcantly milder hearing loss than
that associated with truncating and even other non-
truncating mutations of GJB2.10–12 20
Previous studies of hearing in GJB2 mutation carriers
identiﬁed through genetic testing have shown conﬂicting
results, summarised in supplementary table S1. All of
these are small studies often based on ascertainment of
carriers as the parents or relatives of children with severe/
profound deafness. Morell et al21 showed no/minor differ-
ences in the pure-tone audiograms of c.35delG carriers
compared to controls, as did Engel-Yeger et al.22 23
Conversely, Franzé et al24 showed worse high-frequency
hearing thresholds in c.35delG carriers compared to con-
trols. Using otoacoustic emissions (OAE), perhaps a more
sensitive measure of hearing, carriers showed reduced
amplitude OAE compared to controls, particularly for the
high frequencies. Amplitude differences ranged from
5 dB across 1–4 kHz21 to 1–2 dB across 1–10 kHz.22 23 It
has also been suggested that carriers of GJB2 mutations
may be at greater risk of susceptibility to noise damage.25
However, a study of over 3000 participants found no
increased susceptibility to age or noise exposure in
c.35delG carriers compared to non-carriers.26
The relationship between genotype and phenotype in
those carrying c.101T>C (p.M34T) is even less clear, but
of great interest given the high carrier rate. To our knowl-
edge, there have been no population studies examining
the hearing of c.101T>C (p.M34T) carriers. However,
studies of families with hearing loss have shown a varying
effect of c.101T>C (p.M34T) on hearing. Bicego et al15
studied seven families with c.101T>C (p.M34T) and
hearing impairment. Within these families, there were 11
c.101T>C (p.M34T) heterozygotes of which 5 had
hearing loss. However, in several of these families,
c.101T>C (p.M34T) did not segregate with hearing loss
and some families appeared to have had dominantly
inherited hearing losses.
In addition, these studies were all conducted on adults
and it is not clear as to when in the life course these dif-
ferences might arise. There is thus a need to accurately
determine the UK carrier rate for GJB2 mutations and
to further investigate the audiological proﬁle of carriers
within a population to determine whether previously
found differences in hearing and OAE in adults are
present in childhood. The aims of this study were ﬁrst to
determine the carrier rate of c.35delG mutations and
c.101T>C (p.M34T) in a large UK prospective popula-
tion, the Avon Longitudinal Study of Parents and
Children (ALSPAC) and second to compare hearing
thresholds up to 16 kHz and transient evoked OAEs in
carriers of the GJB2 mutations c.35delG and c.101T>C
with non-carriers at age 7, 9 and 11 years age. These
issues have not been adequately addressed in the litera-
ture using a prospective study design with a large sample
of participants unselected for hearing or genetic status.
MATERIALS AND METHODS
Avon Longitudinal Study of Parents and Children
This study uses data from ALSPAC, a large UK prospect-
ive population study of child development. ALSPAC
recruited 14 541 pregnant women resident in Avon, UK
with expected dates of delivery 1 April 1991–31
December 1992. A wide range of information was col-
lected on the mothers and their offspring, including
detailed information about the mother during preg-
nancy, birth and medical history of the child, repeat
physical and psychological measures of the child and
educational outcomes.27 The proﬁle of the cohort has
been recently described;28 of relevance to this study is
the ethnicity of the children enrolled within ALSPAC
who were predominantly white (96.09%). The follow-up
and attrition rate of the enrolled sample over time are
also described.28 For further general information about
ALSPAC, see http://www.bristol.ac.uk/alspac/.
From age 7, the whole cohort was invited to attend a
regular half day assessment ‘Focus clinic’ at the University
of Bristol. As part of these clinics, blood samples were
obtained for DNA analysis and at three clinics, hearing
was assessed.
Ethical approval for the study was obtained from the
ALSPAC Law and Ethics Committee and the Local
Research Ethics Committees.
DNA analysis
DNA was extracted from cord blood and blood samples
collected at Focus clinics.29 DNA from the ALSPAC
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cohort was screened by KBioScience following successful
‘blind’ validation of the assay using known positive and
negative controls. Single-nucleotide polymorphism geno-
typing for the presence of both c.101T>C and c.35delG
was performed by competitive allele PCR (KASPar) and
TaqMan genotyping assays (www.kbioscience.co.uk/
genotyping/genotyping-chemistry.htm).
Hearing and middle-ear measures
At age 7, 9 and 11 years, children were assessed with
pure-tone audiometry using Kamplex AD12 and GSI 61
audiometers at age 7, and a GSI 61 audiometer at age 9
and 11, with TDH 39 headphones, calibrated to ISO
389.30 Air conduction thresholds were measured at
0.5–8 kHz, and bone conduction thresholds at 0.5–4 kHz
according to the British Society of Audiology recom-
mended procedure for audiometry.31 At age 7 and 9,
extra-high-frequency hearing thresholds were measured
at 16 kHz using the GSI 61 audiometer with circumaural
HDA200 headphones. The 16 kHz threshold was only
measured where time permitted. Tympanometry was
measured using a Kamplex AT2 tympanometer at age 7
and a GSI 38 tympanometer at age 9 and 11 years.
Measures at age 7 were taken in a quiet room and at 9
and 11 in a sound-treated booth. All tests were carried
out by qualiﬁed audiologists or testers specially trained
for this purpose. All staff underwent regular audits to
assess their reliability on audiometry. Testers were blind
to the results of previous hearing tests when performing
audiometry and to the genetic status of the children. If a
hearing loss was measured at the Focus clinic, parents
were given a copy of the results and advised to consult
their child’s general physician.
Otoacoustic emissions
At age 9 and 11 years, transient evoked otoacoustic emis-
sions were recorded using the Otodynamics ILO92
system. Click stimuli were presented at a gain of
−10.5 dB and −19.5 dB (re: reference click at ∼80 dB
sound pressure level (SPL)) and recordings made in the
linear mode. These settings were used as lower-level
stimuli may be more sensitive to changes and differences
in cochlear function.32
Analysis of OAE waveforms here concentrates on the
measure that is conventionally named as response,
which is the SPL of the recorded components that are
common to the two interleaved averages obtained
during recording, conventionally denoted by A and B.
Analogous to the way that the power of a signal is
obtained mathematically by summating across frequency
the product of the Fourier transform of the signal and
its complex conjugate, the response measure is derived
by summating across frequency the real part of the cross-
product of the Fourier transform of A and the complex
conjugate of the Fourier transform of B. The real part
contains only those components that are in phase in A
and B. This measure can simply be considered as an esti-
mate of the OAE signal after removal of the noise. The
response measure was obtained from the raw (unﬁl-
tered) recordings and also after ﬁltering into frequency
bands centred on 1, 2, 3 and 4 kHz. Each ﬁlter had a
bandwidth of 1 kHz.
OAE amplitudes, as deﬁned by the response measure,
of the broadband wave and at 1, 2, 3 and 4 kHz were
used as outcomes.
Sociodemographic data
Information on child sex (male/female), ethnicity
(white/non-white), birthweight, gestation, maternal age
and highest level of maternal education (<16, 16 and
>16 years) was available from medical records, clinic
visits and parental self-completion questions. These data
were used to describe the sociodemographics of the
sample and to compare to those with no genetic and
hearing data available.
The relationship of child sex and ethnicity with
hearing and carrier status was investigated for possible
confounding.
Statistical analysis
Univariate linear regression analyses were performed to
analyse associations between carrier status (carrier of
c.35delG mutation/non-carrier; carrier of c.101T>C/
non-carrier) and hearing/OAE outcomes. Both genetic
variables were included in the analyses to allow direct
comparison of effect sizes. To increase the statistical
power, right and left ear hearing thresholds and right
and left OAE amplitude data were averaged for each par-
ticipant. Analyses were performed using STATAV.11.0.
RESULTS
Sample
Genetic data were available on 9631 children of the whole
cohort whose parents consented for biological samples to
be taken at clinical visits. Of these 9631 samples, genotyp-
ing was successfully performed on 9202 samples (95.5%).
Their characteristics and how they compare with the rest
of the ALSPAC cohort are shown in table 1. As is typically
seen in epidemiological studies the study sample was more
advantaged than the rest of the cohort. There was an
under-representation of non-white children and an over-
representation of children from older, more educated
mothers in the study sample. The children in the study
sample also had a higher birthweight and a longer gesta-
tion period.
Carrier rate
The c.35delG and c.101T>C mutation rate is summarised
in table 2. This shows a carrier rate of 1.36% (95% CI
1.13% to 1.62%) for c.35delG and 2.69% (95% CI 2.37%
to 3.05%) for c.101T>C. Three cases, 0.03% (95% CI
0.006% to 0.09%) were homozygous for c.101T>C, see
ﬁgure 1 for their audiograms. None of the participants
carried both the c.35delG mutation and c.101T>C.
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There was no evidence of disequilibrium for either the
c.35delG mutation (p=0.510) or c.101T>C (p=0.334).
The sex and ethnicity characteristics of the sample
were examined to determine whether these varied with
both the carrier status and hearing thresholds, and thus
could confound the results. Table 3 shows the sample
characteristics according to carrier status. There was evi-
dence of a weak association between child ethnicity and
c.101T>C carrier status (p=0.026), but not between
child ethnicity and average hearing thresholds at age 7
(left ear p=0.584; right ear p=0.207). There was no evi-
dence of a sex difference between carriers and non-
carriers for c.35delG (p=0.457) or c.101T>C (p=0.387),
although there was a relationship between sex and
average hearing threshold with females having worse
hearing than males (age 7 results: left ear p=0.076; right
ear p=0.000). As carrier status and hearing thresholds
did not vary consistently with sex and ethnicity, con-
founding is unlikely and therefore unadjusted statistical
results are presented. Analyses were also performed
excluding non-white children from the sample, and
these gave essentially the same results, see supplemental
tables S2 and S3.
Hearing thresholds
Hearing data from at least one time point were available
on 97 out of 125 c.35delG carriers and 190 of 246
c.101T>C carriers. Figure 2 displays the mean audiomet-
ric hearing thresholds for carriers and non-carriers at age
11 showing that the mean thresholds of the carrier and
non-carrier groups were all within the normal range.
At age 7, 7774 of the cohort had hearing thresholds
measured, at age 9 it was 7379 and at age 11 it was 7111.
As described for the genetic data, those children attend-
ing the Focus clinics were more likely to be advantaged
compared with the rest of the cohort. Cases where both
hearing threshold and genotype data were available were
used in linear regression analysis to estimate the differ-
ence in hearing thresholds between carriers and non-
carriers for each of the frequencies tested at age 7, 9
and 11. Fewer than half the children had data for
16 kHz due to time constraints. The c.35delG results of
the regression analysis are shown in table 4 and the
c.101T>C results in table 5. For the c.35delG mutation
there was no evidence that the carriers had worse
hearing thresholds at the conventional audiometric fre-
quencies. However, at 16 kHz there was strong evidence
of a difference between the two groups with carriers
having mean thresholds 8 dB worse than non-carriers at
age 7, increasing to 12 dB at age 9.
For c.101T>C there was no evidence of a difference in
hearing threshold between carriers and non-carriers at
the conventional audiometric frequencies. At 16 kHz,
there was evidence of worse hearing in the carrier group
at age 9 and 11, with hearing 3 dB and 7 dB worse,
respectively.
There was weak evidence that carrying the c.35delG
mutation had a larger effect than c.101T>C on 16 kHz
hearing thresholds at age 9 (p=0.111) and 11 (p=0.079).
Otoacoustic emissions
OAE results obtained at the two different stimulus levels
were analysed which showed essentially the same results
Table 1 Characteristics of the study sample compared with the remaining ALSPAC cohort
Sample with genetic information
(either c.35delG or c.101T>C) (n=9202) Rest of ALSPAC cohort (n=5321) p Value
Sex (% males) 51.85 50.78 0.215
Child’s ethnicity (% non-white) 4.33 6.43 0.000
Mean birthweight (g) (SD) 3422.56 (543.25) 3339.68 (582.17) 0.000
Mean gestation (weeks) (SD) 39.44 (1.81) 39.30 (2.10) 0.000
Mean age of mother (years) (SD) 28.48 (4.83) 27.15 (5.06) 0.000
Maternal highest education
qualification (%)
<16 years 26.43 39.96 0.000
16 years 35.17 34.59
>16 years 38.43 35.38
ALSPAC, Avon Longitudinal Study of Parents and Children.
Table 2 Summary of GJB2 mutation carrier rate in Avon Longitudinal Study of Parents and Children
Homozygote (%) (n) Heterozygote (%) (n) Homozygote recessive Total N
c.35delG G:G G:−
98.63 (9014) 1.36 (125) 0 (0) 9139
c.101T>C T:T C:T C:C
97.27 (8863) 2.69 (246) 0.03 (3) 9112
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for the lower and higher stimulus level settings. There
was no evidence that lower stimulus settings were more
sensitive to differences between groups and therefore
only higher-stimulus-level results are shown.
Linear regression was used to compare the OAE amp-
litude across frequency for carriers and non-carriers.
Table 6 shows the difference in amplitude at age 9 and
11 for the carriers and non-carriers (OAE were not
recorded at age 7). At age 9 the c.35delG carrier group
had smaller OAE amplitude compared to non-carriers
across the frequency range, with the largest differences
at 3 and 4 kHz. A similar pattern was observed at age 11,
although the differences were slightly smaller.
For c.101T>C there was evidence of smaller OAE amp-
litude at 4 kHz in the carriers at age 9 but not at 11.
There was strong evidence that carrying the c.35delG
mutation had a larger effect than c.101T>C on OAE
amplitude at age 9 (1 kHz, p=0.008; 2 kHz, p=0.011;
Figure 1 Audiograms of the three cases homozygous for c.101T>C. The most recent and complete data are shown. (A) Case 1
at age 7, (B) case 2 at age 11, (C) case 3 at age 9.
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3 kHz, p=0.001 and 4 kHz, p=0.001); the evidence was
weaker at age 11 (1 kHz, p=0.295; 2 kHz, p=0.046; 3 kHz,
p=0.141 and 4 kHz, p=0.009).
DISCUSSION
Carrier rate
This study is one of the largest of its type where children
were unselected for hearing status and tested as part of
a prospective population study of development. ALSPAC
is broadly representative of the UK in terms of sociode-
mographics albeit with a lower proportion of ethnic
minorities. The results reported here are likely to be
broadly generalisable for a white UK population.
The prevalence of c.35delG carriers in the ALSPAC
cohort was 1.36% (95% CI 1.13% to 1.62%) which is
consistent with the ﬁgure of 1.53% (95% CI 1.26% to
1.83%, calculated from data provided in the paper)
given by Mahdieh and Rabbani5 for Northern Europe.
The prevalence of c.101T>C in this study was 2.69%
(95% CI 2.37% to 3.05%), which is double that of
c.35delG and lower than the rate of 5.81% (95% CI
4.44% to 7.44%, calculated from data provided in the
paper) found in Estonia33 based on a sample size of
998. There were no cases carrying both the c.35delG
mutation and c.101T>C in ALSPAC. Three cases
(0.03%) were homozygous for c.101T>C. There was
weak evidence that c.101T>C was less likely to be present
in non-white children.
Hearing thresholds and otoacoustic emissions
in c.35delG carriers
There was no effect of carrier status on hearing at the
conventional audiometric thresholds examined at 7, 9
Figure 2 Mean audiograms at
age 11. (A) c.35delG
non-carriers, (B) c.35delG
carriers, (C) c.101T>C
non-carriers and (D) c.101T>C
carriers.
Table 3 Characteristics of the sex and ethnicity profile of carriers compared to non-carriers
c.35delG c.101T>C
Non-carriers Carriers Non-carriers Carriers
Sex
n (%) Males 4674 (51.85) 69 (55.20) 4607 (51.98) 121 (49.19)
Child’s ethnicity
n (%) Non-white 342 (4.36) 3 (2.70) 340 (4.41) 3 (1.40)
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Table 4 Differences in hearing threshold between c.35delG carriers at age 7 (n=80), age 9 (n=81) and age 11 (n=77) and non-carriers (unadjusted results)
Age 7 Age 9 Age 11
Air or bone conduction Frequency* (kHz) N Coefficient dB† (95% CI) p Value N
Coefficient dB†
(95% CI) p Value N
Coefficient dB†
(95% CI) p Value
Air 0.5 5892 0.01 (−1.64 to 1.67) 0.985 5697 0.04 (−1.39 to 1.47) 0.953 5429 −0.34 (−1.81 to 1.13) 0.650
1 6147 −0.16 (−1.81 to 1.48) 0.848 5783 0.68 (−0.79 to 2.14) 0.364 5473 −0.79 (−2.23 to 0.64) 0.277
2 6091 −0.58 (−2.18 to 1.01) 0.472 5782 −1.16 (−2.59 to 0.26) 0.112 5472 −1.28 (−2.76 to 0.18) 0.087
3‡ 5431 −1.26 (−2.76 to 0.24) 0.100
4 6144 0.14 (−1.67 to 1.97) 0.872 5782 −0.46 (−2.10 to 1.17) 0.578 5468 −0.75 (−2.33 to 0.83) 0.352
6‡ 5427 −0.67 (−2.53 to 1.19) 0.480
8 6119 0.63 (−1.43 to 2.70) 0.547 5675 0.34 (−1.63 to 2.33) 0.731 5388 −1.04 (−3.00 to 0.91) 0.297
16§ 2860 8.53 (2.99 to 14.07) 0.003 4166 12.57 (8.10 to 17.04) 0.000
Bone¶ 0.5 5581 0.18 (−1.27 to 1.65) 0.800 5444 −0.92 (−2.38 to 0.53) 0.213
1 6001 −0.33 (−1.86 to 1.19) 0.669 5753 −0.75 (−2.18 to 0.66) 0.297 5449 −0.28 (−2.02 to 0.78) 0.388
2 5593 −1.30 (−2.93 to 0.31) 0.113 5445 −1.32 (−2.94 to 0.29) 0.109
4 6107 −0.88 (−2.36 to 0.59) 0.243
*Right and left ear average.
†A positive coefficient means that hearing threshold is higher (ie, worse) in the carrier group compared to the non-carriers.
‡Thresholds at 3 and 6 kHz were measured at age 11.
§Thresholds at 16 kHz were measured at age 7 and 9.
¶Bone conduction thresholds were measured at 1 and 4 kHz at age 7, and at 0.5, 1 and 2 kHz at age 9 and 11.
Table 5 Differences in hearing threshold between c.101T>C carriers at age 7 (n=171), age 9 (n=150) and age 11 (n=135) and non-carriers (unadjusted results)
Age 7 Age 9 Age 11
Air or bone
conduction
Frequency*
(kHz) N
Coefficient dB†
(95% CI)
p
Value N
Coefficient dB†
(95% CI)
p
Value N
Coefficient dB†
(95% CI)
p
Value
Air 0.5 5892 0.30 (−0.82 to 1.42) 0.602 5697 −0.02 (−1.08 to 1.03) 0.961 5429 0.33 (−0.76 to 1.44) 0.550
1 6147 0.64 (−0.49 to 1.78) 0.266 5783 −0.40 (−1.49 to 0.68) 0.466 5473 −0.23 (−1.32 to 0.85) 0.671
2 6091 0.38 (−0.71 to 1.49) 0.491 5782 −0.38 (−1.44 to 0.67) 0.474 5472 −0.57 (−1.69 to 0.55) 0.318
3‡ 5431 −0.74 (−1.87 to 0.38) 0.194
4 6144 0.36 (−0.89 to 1.61) 0.572 5782 0.25 (−0.95 to 1.46) 0.678 5468 0.45 (−0.74 to 1.65) 0.457
6‡ 5427 0.33 (−1.06 to 1.72) 0.641
8 6119 −0.58 (−1.99 to 0.83) 0.422 5675 0.02 (−1.44 to 1.49) 0.971 5458 −0.55 (−2.04 to 0.92) 0.462
16§ 2860 3.25 (−0.25 to 6.75) 0.069 4166 7.61 (4.26 to 10.96) 0.000
Bone¶ 0.5 5581 0.26 (−0.81 to 1.33) 0.635 5444 −0.71 (−1.81 to 0.39) 0.208
1 6001 −0.26 (−1.32 to 0.79) 0.669 5753 0.02 (−1.02 to 1.07) 0.961 5449 −0.28 (−1.35 to 0.78) 0.604
2 5593 0.34 (−0.84 to 1.53) 0.569 5445 −0.72 (−1.95 to 0.50) 0.250
4 6107 0.43 (−0.57 to 1.45) 0.396
*Right and left ear average.
†A positive coefficient means that hearing threshold is higher (ie, worse) in the carrier group compared to the non-carriers.
‡Thresholds at 3 and 6 kHz were measured at age 11.
§Thresholds at 16 kHz were measured at age 7 and 9.
¶Bone conduction thresholds were measured at 1 and 4 kHz at age 7 and at 0.5, 1 and 2 kHz at age 9 and 11.
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and 11 years, consistent with the smaller study of
Engel-Yeger et al.22 Unlike the study by Franzé et al24 we
did not show a difference in hearing at 6 and 8 kHz.
Their study selected participants from a clinical caseload
and were older than the participants in this study, which
may account for the different results.
However at age 7 and 9 years a measure of
extra-high-frequency hearing at 16 kHz was available and
comparison of the hearing thresholds at this frequency
showed c.35delG carriers had hearing thresholds approxi-
mately 5–10 dB worse than non-carriers. There was a
larger difference at age 9 than at age 7, suggesting a wor-
sening in extra-high-frequency hearing between these
ages. This provides evidence of early changes to the
hearing of the carrier group, which although not detect-
able on conventional audiometry may be a predictor of
later changes in hearing in adulthood.
In addition, there was also evidence that OAE ampli-
tude is lower in the c.35delG carrier group: at age 9, the
mean OAE amplitude of carriers was 2–5 dB lower than
non-carriers with the largest differences observed at
4 kHz. At age 11, these differences were still apparent,
although smaller than at age 9, possibly as a result of
fewer cases in the analysis at 11. The poorer hearing
thresholds at 16 kHz in the carrier group may explain
the lower OAE amplitude, as variation in high- and
extra-high-frequency hearing has been shown to explain
differences in lower frequency OAE amplitude.34–36 The
results could also be explained by subclinical damage to
the lower-frequency regions of the cochlea not yet
detectable on the audiogram.
Hearing thresholds and otoacoustic emissions
in c.101T>C carriers
Hearing thresholds and OAE amplitude were examined
for the c.101T>C carriers. There was no evidence of an
effect of carrier status on hearing thresholds at the con-
ventional frequencies at age 7, 9 or 11 years.
Examination of the 16 kHz extra-high-frequency hearing
threshold showed that those carrying c.101T>C had
worse hearing at age 7 and 9. The size of the effect
increased from 3 to 7 dB between these ages. These
results were similar to those obtained for the c.35delG
carriers, although with weak evidence of a smaller effect.
For the OAE results, the evidence was generally weak
that amplitude was lower in the carrier group. At age 9,
the 4 kHz amplitude was 1–2 dB smaller in the carrier
group but this effect was reduced at age 11. These
results suggest that the smaller differences in
extra-high-frequency hearing have a negligible effect on
the lower-frequency OAE and suggest that c.101T>C has
a weaker effect on hearing than carrying c.35delG,
which would be consistent with its effects in individuals
homozygous for c.101T>C. There has been controversy
in the literature as to whether c.101T>C has an inﬂu-
ence on hearing and many c.101T>C homozygotes and
compound heterozygotes have milder hearing loss than
that observed with truncating mutations such as
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c.35delG20 or even normal hearing. The milder effects
we observe here might also suggest reduced penetrance
and/or a later age of onset on hearing as suggested by
others.11
Study limitations
The sample was more advantaged than the whole of the
ALSPAC cohort, as is typical with longitudinal studies of
health and development37 but this should not distort
speciﬁc genotype–phenotype associations. Owing to the
low numbers of non-white children within ALSPAC,28
the results are generalisable to the white UK population
only.
The weaknesses of this study include sample attrition
and thus possible loss of statistical power to detect differ-
ences between the carriers and non-carriers, particularly
for the smaller c.35delG carrier group. Not all the
carrier group had hearing tests performed at each of
the time points and so it is possible that we did not have
the power to detect differences at the conventional
audiometric frequencies. The number of cases available
for the OAE analysis was smaller than those available for
the hearing analysis, and thus power is equally an issue
for these data.
CONCLUSIONS
We have shown that carriers of the c.35delG mutation
and c.101T>C have subtle differences in their audio-
logical proﬁle at age 9 compared to non-carriers at the
extra-high frequencies. This adds further evidence that
c.101T>C is a mild but functional variant with the effect
larger in the c.35delG group. It will be interesting to
observe whether effects become more pronounced with
advancing age.
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